In Sun Ryu1, Jong-Lyel Roh2, Jae Seung Kim3, Jeong Hyun Lee4, Kyung-Ja Cho5, Seung-Ho Choi6, Soon Yuhl Nam6, Sang Yoon Kim6. 1. Department of Otolaryngology, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Republic of Korea. 2. Department of Otolaryngology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Electronic address: rohjl@amc.seoul.kr. 3. Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. 4. Department of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. 5. Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. 6. Department of Otolaryngology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Abstract
BACKGROUND: Accurate assessment of the extent of cancer is essential for appropriate treatment planning and outcome prediction. This study prospectively evaluated whether adding (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography (PET)/computed tomography (CT) to the routine initial staging practice in head and neck squamous cell carcinoma (HNSCC) improved management and prognosis. METHODS: All consecutive patients with newly diagnosed HNSCC who presented in October 2010 - December 2012 underwent conventional workups (CWU) followed by PET/CT. The clinical stage and management plans before and after PET/CT were compared. PET/CT was deemed to have no/low, moderate, and high impact on management planning depending on whether PET/CT changed the treatment modality or goal. The appropriateness of PET/CT staging and management impact was confirmed by histopathology and clinical follow-up, and its association with survival was analysed. FINDINGS: Of the 248 patients, PET/CT changed the Tumour Node Metastasis (TNM) classification in 79 (31.9%). In the patients with discordant staging, PET/CT staging was significantly more sensitive and accurate than CWU staging (both P < 0.001). PET/CT had high or moderate impact on management in 39 (15.7%) patients. Patients with PET/CT upstaged disease had significantly worse progression-free survival (PFS) and overall survival (OS) than patients with no CWU-stage changes (3-year PFS = 56.8% versus 74.5%, P = 0.043; 3-year OS = 61.3% versus 85.3%, P = 0.006). Multivariate analyses revealed that PET/CT staging and second primary cancer were independent predictive factors for both PFS and OS (P < 0.05, each). INTERPRETATIONS: (18)F-FDG PET/CT added important staging information that improved management and prognostic stratification in HNSCC.
BACKGROUND: Accurate assessment of the extent of cancer is essential for appropriate treatment planning and outcome prediction. This study prospectively evaluated whether adding (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography (PET)/computed tomography (CT) to the routine initial staging practice in head and neck squamous cell carcinoma (HNSCC) improved management and prognosis. METHODS: All consecutive patients with newly diagnosed HNSCC who presented in October 2010 - December 2012 underwent conventional workups (CWU) followed by PET/CT. The clinical stage and management plans before and after PET/CT were compared. PET/CT was deemed to have no/low, moderate, and high impact on management planning depending on whether PET/CT changed the treatment modality or goal. The appropriateness of PET/CT staging and management impact was confirmed by histopathology and clinical follow-up, and its association with survival was analysed. FINDINGS: Of the 248 patients, PET/CT changed the Tumour Node Metastasis (TNM) classification in 79 (31.9%). In the patients with discordant staging, PET/CT staging was significantly more sensitive and accurate than CWU staging (both P < 0.001). PET/CT had high or moderate impact on management in 39 (15.7%) patients. Patients with PET/CT upstaged disease had significantly worse progression-free survival (PFS) and overall survival (OS) than patients with no CWU-stage changes (3-year PFS = 56.8% versus 74.5%, P = 0.043; 3-year OS = 61.3% versus 85.3%, P = 0.006). Multivariate analyses revealed that PET/CT staging and second primary cancer were independent predictive factors for both PFS and OS (P < 0.05, each). INTERPRETATIONS: (18)F-FDG PET/CT added important staging information that improved management and prognostic stratification in HNSCC.
Authors: Val J Lowe; Fenghai Duan; Rathan M Subramaniam; JoRean D Sicks; Justin Romanoff; Twyla Bartel; Jian Q Michael Yu; Brian Nussenbaum; Jeremy Richmon; Charles D Arnold; David Cognetti; Brendan C Stack Journal: J Clin Oncol Date: 2019-02-15 Impact factor: 44.544
Authors: Christina Pfannenberg; Brigitte Gueckel; Lisa Wang; Sergios Gatidis; Susann-Cathrin Olthof; Werner Vach; Matthias Reimold; Christian la Fougere; Konstantin Nikolaou; Peter Martus Journal: Eur J Nucl Med Mol Imaging Date: 2018-09-29 Impact factor: 9.236
Authors: A Nøhr; S B Gram; B Charabi; J F Tvedskov; I Wessel; J Friborg; K Håkansson; C von Buchwald; B M Fischer; Jacob H Rasmussen Journal: Eur Arch Otorhinolaryngol Date: 2019-07-11 Impact factor: 2.503
Authors: Shlomo A Koyfman; Nofisat Ismaila; Doug Crook; Anil D'Cruz; Cristina P Rodriguez; David J Sher; Damian Silbermins; Erich M Sturgis; Terance T Tsue; Jared Weiss; Sue S Yom; F Christopher Holsinger Journal: J Clin Oncol Date: 2019-02-27 Impact factor: 44.544
Authors: Joshua K Cho; Thomas J Ow; Andrew Y Lee; Richard V Smith; Nicolas F Schlecht; Bradley A Schiff; Andrew B Tassler; Juan Lin; Renee M Moadel; Ana Valdivia; Tony Abraham; Edwin Gulko; Matthew Neimark; Berrin Ustun; Jacqueline A Bello; Keivan Shifteh Journal: Otolaryngol Head Neck Surg Date: 2017-06-13 Impact factor: 3.497
Authors: Jeffery B Jorgensen; Russell B Smith; Andrew Coughlin; William C Spanos; Michele M Lohr; Steven M Sperry; Oleg Militsakh; Robert P Zitsch; Bevan Yueh; Laura M Dooley; Aru Panwar; Tabitha L I Galloway; Nitin A Pagedar Journal: Otolaryngol Head Neck Surg Date: 2018-08-21 Impact factor: 3.497